Orkambi OK'd; Vertex prices new CF drug at $259k

The FDA's 2 July approval of Vertex Pharmaceuticals' new cystic fibrosis drug Orkambi came as little surprise, with everyone on Wall Street anticipating the agency would make its move ahead of the 4 July US Independence Day holiday – in which federal offices are closed on 3 July – and the 5 July Prescription Drug User Fee Act action date.